Bridge to Affective Wellness PLLC
In 2022, Bridge to Affective Wellness, PLLC, was formed. Affect, as defined by Merriam-Webster, is "a set of observable manifestations of an experienced emotion. Mood Disorders may be complicated, treatment resistant, and require new or unconventional treatments to obtain a response. Treatment resistant depression or other mood disorders may not respond to just one medication. If you or a love one have taken two or more antidepressants or have adverse reactions to the medications causing discontinuation, without response, treatment resistant depression may be the case. For the past 50 years antidepressant medications have mainly focused on serotonin/norepinephrine brain systems; we have discovered use of ketamine for treatment resistant depression. We are treating patients with treatment resistant depression with Spravato, which obtained FDA indication for such in 2019.
Treatment Resistant Depression (TRD): Depression which has not adequately responded to two more trials of antidepressants (at effective doses); or intolerable side effects to antidepressants tried.
Spravato (Esketamine) Received FDA Indication for treatment resistant depression in 2019.
Patients self administer nasal spray into both nostrils, while under physician supervision. Patients must remain in office for 120 minutes and must have a ride home after treatment.